The U.S. Food and Drug Administration has approved Roche immunotherapy drug Tecentriq as a first-line treatment for patients with advanced bladder cancer who are not eligible for standard cisplatin chemotherapy. The greenlight was given to Roche subsidiary Genentech under the FDA's accelerated approval program.
Tecentriq had already won approval for treating patients with advanced or metastatic bladder cancer whose disease worsened within a year of receiving chemotherapy. Six months ago, the FDA had already approved the drug, also known as atezolizumab, to treat non-small cell lung cancer.
Read the Reuters report